Sign In
to Vote &
Create Storyboards.
 
The National Cancer Institute (INCan) has progressed from a rate of nine months of survival to 30 with personalized treatments for patients diagnosed with lung cancer in metastatic stage, i.e., when the disease has spread to different parts of the body.In Mexico, as elsewhere, it is possible to give personalized treatment such as biomarkers and oral drugs to patients with this disease that have presented mutations in the epidermal growth factor.
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard